FRA:NOV - Deutsche Boerse Ag - DK0062498333 - Common Stock - Currency: EUR
We assign a fundamental rating of 7 out of 10 to NOV. NOV was compared to 51 industry peers in the Pharmaceuticals industry. NOV has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NOV is growing strongly while it is still valued neutral. This is a good combination! These ratings could make NOV a good candidate for growth and quality investing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.39% | ||
ROE | 75.51% | ||
ROIC | 44.39% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 46.51% | ||
PM (TTM) | 34.51% | ||
GM | 84.33% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.7 | ||
Debt/FCF | 1.6 | ||
Altman-Z | 5.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.74 | ||
Quick Ratio | 0.56 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.26 | ||
Fwd PE | 13.63 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 27.04 | ||
EV/EBITDA | 12.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.33% |
FRA:NOV (6/24/2025, 5:29:00 PM)
60.67
+0.49 (+0.81%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 2.33% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 19.26 | ||
Fwd PE | 13.63 | ||
P/S | 6.63 | ||
P/FCF | 27.04 | ||
P/OCF | 15.32 | ||
P/B | 14.52 | ||
P/tB | 68.96 | ||
EV/EBITDA | 12.85 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.39% | ||
ROE | 75.51% | ||
ROCE | 55.72% | ||
ROIC | 44.39% | ||
ROICexc | 53.11% | ||
ROICexgc | 110% | ||
OM | 46.51% | ||
PM (TTM) | 34.51% | ||
GM | 84.33% | ||
FCFM | 24.53% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.7 | ||
Debt/FCF | 1.6 | ||
Debt/EBITDA | 0.6 | ||
Cap/Depr | 284.1% | ||
Cap/Sales | 18.77% | ||
Interest Coverage | 108.03 | ||
Cash Conversion | 81.52% | ||
Profit Quality | 71.08% | ||
Current Ratio | 0.74 | ||
Quick Ratio | 0.56 | ||
Altman-Z | 5.23 |